While Eli Lilly celebrated a “solid quarter” of earnings this morning, a look over the Big Pharma’s third-quarter presentation reveals that the company has quietly dumped two clinical-stage assets.
At the time of the deal, Fosun hyped up BCL-2 as an “increasingly important therapeutic target in cancer biology.” Lilly presumably agreed, handing over $40 million and pledging up to $400 million to follow in potential biobucks. AbbVie and Roche have previously scored success by bringing the first BCL-2 inhibitor to market in the form of leukemia drug Venclexta.
The midstage study kicked off in November 2020 and was due to complete at the end of September 2022, according to ClinicalTrials.gov. It’s not clear whether a peek at the data spooked Lilly into dropping the drug.
Lilly had not responded to Fierce Biotech’s request for more information on the discontinuations at time of publication.